Nuvation Bio (NUVB) Research & Development (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Research & Development of $35.0 million for Q1 2026, up 42.46% year-over-year from $24.6 million in Q1 2025, and up 2.19% quarter-over-quarter from $34.3 million in Q4 2025.
Nuvation Bio (NUVB) Research & Development (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Research & Development for 7 consecutive years, with $35.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 42.46% year-over-year to $35.0 million; the TTM figure through Mar 2026 stood at $125.6 million (up 13.23% YoY), while the FY2025 annual figure was $115.1 million, up 16.13% from the prior year.
- Research & Development advanced to $35.0 million in Q1 2026 per NUVB's latest filing, from $34.3 million in the prior quarter.
- Across five years, Research & Development topped out at $35.0 million in Q1 2026 and bottomed at $12.8 million in Q1 2024.
- Historically, Research & Development has averaged $24.0 million across 5 years, with a median of $24.6 million in 2025.
- Annual changes were most pronounced in 2022 — Research & Development soared 106.09% — and 2023, when it plunged 35.72%.
- Nuvation Bio's Research & Development stood at $16.9 million in 2022, then fell by 9.01% to $15.4 million in 2023, then jumped by 90.86% to $29.3 million in 2024, then increased by 17.06% to $34.3 million in 2025, then climbed by 2.19% to $35.0 million in 2026.
- Business Quant data shows NUVB's Research & Development at $35.0 million in Q1 2026, $34.3 million in Q4 2025, and $28.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 30.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.66 Mn |
| Mar 31, 2026 | 35.05 Mn |
| Dec 31, 2025 | 34.30 Mn |
| Sep 30, 2025 | 28.85 Mn |
| Jun 30, 2025 | 27.36 Mn |
| Mar 31, 2025 | 24.60 Mn |
| Dec 31, 2024 | 29.30 Mn |
| Sep 30, 2024 | 27.73 Mn |
| Jun 30, 2024 | 29.25 Mn |
| Mar 31, 2024 | 12.84 Mn |
| Dec 31, 2023 | 15.35 Mn |
| Sep 30, 2023 | 18.56 Mn |
| Jun 30, 2023 | 18.59 Mn |
| Mar 31, 2023 | 18.79 Mn |
| Dec 31, 2022 | 16.87 Mn |
| Sep 30, 2022 | 21.29 Mn |
| Jun 30, 2022 | 28.92 Mn |
| Mar 31, 2022 | 20.73 Mn |
| Dec 31, 2021 | 22.00 Mn |
| Sep 30, 2021 | 17.12 Mn |